Can a 'Longevity' molecule reach the brain and fight Alzheimer's?

NCT ID NCT05040321

Completed Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial tests whether MIB-626, a drug that activates sirtuin-NAD pathways, can reach the brain and affect aging-related markers in people with mild Alzheimer's. 22 participants will take either MIB-626 or a placebo for 90 days. The study primarily checks if the drug enters the cerebrospinal fluid and engages its target, not whether it improves memory or daily function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MIB-626 (a sirtuin-NAD activator)
What this could lead to: If successful, this could point toward a treatment that targets multiple Alzheimer's-related processes, like brain energy and inflammation.
What could go wrong: This is a very small, early-phase trial with only 22 people, focused on safety and brain penetration—not on whether the drug improves symptoms or slows the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE (INCL SUBTYPES) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE (INCL SUBTYPES) DEMENTIA

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115-0000, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.